untitled design

Coreper launches data evaluation to extend use of ‘Imvanex’ to monkeypox protection

The European Medicines Agency (EMA) announced today that it has launched a data evaluation to extend the use of the “Imvanex” smallpox vaccine to include protection against monkeypox.

Imvanex is currently approved in the EU for the prevention of smallpox in adults. It contains a live modified form of the vaccinia virus called “vaccinia Ankara”, which is associated with the smallpox virus. It is also considered a possible vaccine for monkey pox because of the similarity between the monkey pox virus and the smallpox virus.

The decision to initiate this data evaluation is based on the results of laboratory studies (non-clinical data) which suggest that this vaccine activates the production of antibodies that target the monkey pox virus and may help protect against the disease.

In a statement, Coreper noted that Imvanex supplies are currently very limited in the EU. Imvanex is marketed as Jynneos in the US where it is approved to prevent both monkeypox and smallpox.

Source: AMPE

Source: Capital

You may also like

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular